# Title page

**Functional Cognitive Disorder - dementia's blind spot**

# Authors & affiliations:

Harriet A. Ball – Population Health Sciences, University of Bristol

Laura McWhirter – Centre for Clinical Brain Sciences, The University of Edinburgh

Clive Ballard – College of Medicine and Health, University of Exeter

Rohan Bhome – Division of Psychiatry, University College London

Daniel J. Blackburn – Department of Neuroscience, Medical School, The University of Sheffield

Mark J. Edwards – Neuroscience research Centre, St George’s, University of London

Stephen M. Fleming – Wellcome Centre for Human Neuroimaging, University College London

Nick C. Fox – Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Queen Square Institute of Neurology

Robert Howard – Division of Psychiatry, University College London

Jonathan Huntley – University College London

Jeremy D. Isaacs – Department of Neurology, St George’s University Hospitals NHS Foundation Trust, London and Neuroscience Research Centre, St George’s, University of London

A.J. Larner – Cognitive Function Clinic, Walton Centre for Neurology and Neurosurgery, Liverpool

Timothy R. Nicholson – Institute of Psychiatry Psychology & Neuroscience, King’s College London

Catherine M. Pennington – Centre for Dementia Prevention, The University of Edinburgh

Norman Poole - St George’s, University of London

Gary Price – University College London Hospitals NHS Foundation Trust

J.P. Price – Department of Neuropsychology, South Tees Hospitals NHS Foundation Trust

Markus Reuber – Department of Neuroscience, Medical School, University of Sheffield

Craig Ritchie – Centre for Dementia Prevention, The University of Edinburgh

Martin N. Rossor – Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Queen Square Institute of Neurology

Jonathan M. Schott – Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Queen Square Institute of Neurology

Tiago Teodoro - St George’s, University of London; and Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal

Annalena Venneri – Department of Neuroscience, Medical School, The University of Sheffield

Jon Stone – Centre for Clinical Brain Sciences, The University of Edinburgh

Alan J. Carson – Centre for Clinical Brain Sciences, The University of Edinburgh

# Abstract:

An increasing proportion of cognitive difficulties are recognised to have a functional cause, the chief clinical indicator of which is internal inconsistency. When these symptoms are impairing or distressing, and not better explained by other disorders, this can be conceptualised as a cognitive variant of Functional Neurological Disorder (FND), termed Functional Cognitive Disorder (FCD). FCD is likely very common in clinical practice but may be under-diagnosed. Clinicians in many settings make liberal use of the descriptive term Mild Cognitive Impairment (MCI) for those with cognitive difficulties not impairing enough to qualify as dementia. However, MCI is an aetiology-neutral description, which therefore includes patients with a wide range of underlying causes. Consequently, a proportion of MCI cases are due to non-neurodegenerative processes, including FCD. Indeed, significant numbers of patients diagnosed with MCI do not "convert" to dementia. The lack of diagnostic specificity for MCI "non-progressors" is a weakness inherent in framing MCI primarily within a deterministic neurodegenerative pathway. It is recognised that depression, anxiety and behavioural changes can represent a prodrome to neurodegeneration; empirical data are required to explore whether the same might hold for subsets of people with FCD. Clinicians and researchers can improve study efficacy and patient outcomes by viewing MCI as a descriptive term with a wide differential diagnosis, including potentially reversible components such as FCD. ​​We present a preliminary definition of Functional Neurological Disorder- Cognitive Subtype, explain its position in relation to other cognitive diagnoses and emerging biomarkers, highlight clinical features that can lead to positive diagnosis (as opposed to a diagnosis of exclusion), and red flags that should prompt consideration of alternative diagnoses. In the research setting, positive identifiers of FCD will enhance our recognition of individuals who are not in a neurodegenerative prodrome, while greater use of this diagnosis in clinical practice will facilitate personalised interventions.

# Abbreviations:

FCD: Functional Cognitive Disorder

MCI: Mild Cognitive Impairment

SCD: Subjective Cognitive Decline

DSM-5: Diagnostic and Statistical Manual, 5th edition

FND: Functional Neurological Disorder

# Main text:

**Overlapping definitions**

Functional Cognitive Disorder (FCD) refers to complaints of persistent problematic cognitive difficulties, when accompanied by positive features termed “internal inconsistency” (see Text Box 1), and which are not better explained by another disorder e.g., a neurodegenerative disease process (see Text Box 2 for full FCD criteria). This is relevant to all clinicians to whom such patients present, including in general practice, gerontology, neurology, psychiatry and others. FCD is likely common but is rarely diagnosed, perhaps in part because such patients usually concurrently meet descriptive criteria for either Mild Cognitive Impairment (MCI), or Subjective Cognitive Decline (SCD). MCI is a syndrome involving objective cognitive decline greater than expected for age, that does not interfere with activities of daily life (Albert *et al.*, 2011). SCD describes subjective concern regarding decline in cognitive abilities without evidence of objective cognitive deficit (Howard, 2020; Jessen *et al.*, 2020). Conceptually, both SCD and MCI are heterogeneous concepts and include people with a variety of underlying causes (Blackburn *et al.*, 2014), including neurodegenerative diseases, medical or psychiatric diagnoses, medication and alcohol or other recreational drug effects, and FCD. See Figure 1 for an illustration. However, in practice, the majority of research involving MCI and/ or SCD has been predicated on a linear progression from SCD through MCI to dementia, which is problematic if most of these patients do not in fact have underlying neurodegenerative disease.

Biomarkers that predict Alzheimer’s pathology in particular, or neurodegeneration more generally (including but not limited to MR and PET imaging, genetics, and blood or CSF measurement of amyloid, tau and neurofilament) are already finding utility in clinical trials and are increasingly used in clinical practice. However, while biomarkers may provide evidence for or against a diagnosis of Alzheimer’s disease, a positive diagnosis of FCD on clinical grounds has a number of potentially important complementary roles. First, patients with FCD are likely to benefit from distinct strategies to help with their symptoms. Second, having FCD may prove to be an important exclusion criterion for clinical trials, or may need to be taken into account when interpreting the results of trials targeting Alzheimer’s pathology to reduce heterogeneity. Thirdly, since a dual diagnosis of FCD, and cognitive impairment secondary to Alzheimer’s pathology, is entirely possible (indeed such dual diagnoses are common in other areas of neurology), optimal treatment strategies may need to focus both on FCD and Alzheimer’s pathology. And finally, as we move to diagnosing patients ever earlier, communicating biomarker results may precipitate FCD in people who would otherwise not have manifest symptoms for some time.

Patients with FCD are increasingly prevalent in tertiary memory clinics (comprising 12-56% of new referrals) . Different case definitions may explain how some FCD case series score predominantly normally on objective cognitive testing, whereas others underperform or demonstrate inconsistencies in some areas of objective testing. Note that symptoms in FCD are not feigned. Where tested, patients with functional disorders do not consistently fail tests of Performance Validity or “effort”, but may display impaired selective attention (Teodoro *et al.*, 2018). We encounter many patients who pass performance validity testing but score greater than two standard deviations below normal on standardised cognitive testing (i.e., falling into the FCD/MCI overlap area on Figure 1). Population-based identification of MCI cases may over-recruit people with FCD, as they may be younger, more aware of research opportunities and more open to recruitment efforts.

**De-emphasising the inevitable expectation of progression (from SCD to MCI to Alzheimer’s dementia)**

Understanding the prodromal phase of dementia is clearly of great importance for elucidation of causal mechanisms and development of novel interventions for Alzheimer’s pathology. However, a substantial proportion of people with MCI will later return to normal cognitive function, or maintain stable cognition, rather than showing progressive deterioration. Neuropathological analyses of cohorts who met MCI criteria before death show they are intermediate between those with normal cognition and those with dementia (Stephan *et al.*, 2012). In highlighting such associations, few reports focus on the substantial proportion of individuals with MCI whose brains are histologically normal (Schneider *et al.*, 2009; Abner *et al.*, 2017). It is also difficult to define a clear boundary between age-normative neuropathological changes and the burden of neurodegeneration which is required for cognitive impairment (Ferrer, 2012). There are many reasons why autopsy studies might miss very early neurodegeneration, such as subtle or not-yet-understood pathologies, varying degrees of immunohistochemical analysis and regional brain sampling (Nelson *et al.*, 2012). Regardless, these factors do not fully explain the phenomenon of MCI in the presence of minimal or no brain pathology. In addition, many people with demonstrable neuropathological changes associated with Alzheimer’s disease identified after death did not experience cognitive symptoms in life (Latimer *et al.*, 2017), raising the possibility that only a proportion of the cognitive symptoms experienced by those with neuropathology, might be caused by that pathology.

There is clearly a biological trajectory in Alzheimer’s disease, with the clinical syndrome usually preceded by an MCI phase (Jack *et al.*, 2010). However, it is important not to extrapolate this backwards to assume that all or most people with MCI are on this trajectory *en route* to dementia, because this downplays the importance of other (including FCD) explanations for MCI. Many studies emphasise “conversion” to dementia (e.g., Annualised Conversion Rates of MCI to dementia), which implies a deterministic relationship between MCI and Alzheimer’s dementia (as well as implying an abrupt step-change). Biomarkers are increasingly being used to identify risk of clinical progression on an individual basis (van Maurik *et al.*, 2019) but are as yet imperfect and not always available; and in general there tends to be less focus on the causes of cognitive symptoms in those who do not progress to dementia. A population based analysis that tracked these changes over 7 years, found that 53% remained as MCI cases, while 35% reverted to normal cognition (Ganguli *et al.*, 2019). A default assumption that neurodegeneration underlies MCI may be reinforced amongst clinicians and researchers who frequently interact with people affected by established dementia (i.e., people who *have* passed through MCI as part of a neurodegenerative trajectory). In the wider population however, and especially in older people, other non-neurodegenerative aetiologies and multifactorial processes are likely to contribute significantly (Petersen *et al.*, 2014). Figure 2 (adapted from (McWhirter *et al.*, 2019)) illustrates how heterogeneous trajectories in FCD can account for some of the above mentioned discrepancy. Assumptions of progression may also contribute to widespread public anxiety regarding the inevitability of dementia.

**Diagnosis and aetiology of FCD**

Typical clinical presentations of FCD most commonly focus around memory impairment (often alongside attention and concentration difficulties), often in the form of “memory perfectionism” and mnestic block (Pennington *et al.*, 2015b). FCD less often involves non-amnestic cognitive functions such as praxis, language , or executive function. Current data suggest the typical age at onset of FCD is mid-life (therefore overlapping with early-onset neurodegeneration) (Pennington *et al.*, 2015a; Bharambe and Larner, 2018a; Wakefield *et al.*, 2018), but this may in part reflect the composition of specialist clinics, with referral patterns influenced by the increased likelihood of neurodegeneration in older ages. As with people in the prodromal stage of neurodegenerative dementia, those with FCD are often understandably anxious about their symptoms, are able to discuss their difficulties and coping strategies, and can display mild but persistent deficits (including those seen on objective standardised cognitive tests, or as observed by others in the general course of life), with few other clinical signs.

FCD definitions still lack consensus, hindering our understanding of prevalence particularly in community settings (Stone *et al.*, 2015), and hindering wider understanding and acceptance of the diagnosis. Diagnostic difficulty around FCD exists for several reasons. Firstly, the presence of mnestic concern, and the cognitive trajectory over the short term, may look similar across FCD and early neurodegeneration. Secondly, there is frequently co-occurrence of functional cognitive symptoms alongside some combination of neurodegeneration, general medical, psychiatric or surgical problems, or drug toxicity. In this context, the functional symptoms may be secondary, in the form of a “functional overlay”, although in the clinic setting it is often difficult to differentiate this from the background cognitive symptoms due to identified comorbidities (including substances used). Unfortunately, this distinction is not aided by research studies that often exclude people with mental health conditions, despite their being very common in memory clinic. Thirdly, FCD symptoms often persist over time (Schmidtke *et al.*, 2008), so for example will still feature in MCI studies that check for the persistence of symptoms. Longer-term outcomes of FCD have not been thoroughly studied, although the default assumption should be that affected individuals have the same chance of later developing neurodegeneration as the background population (without such an occurrence indicating a “missed” earlier diagnosis of neurodegeneration). However, this does require empirical testing, because in certain contexts FCD could arise as a prodrome to neurodegeneration (as has been found with certain presentations of late life anxiety, depression and Mild Behavioural Impairment (Livingston *et al.*, 2017; Creese *et al.*, 2019)). These difficulties, and the recent entry of FCD into the cognitive diagnostic lexicon, likely explain why FCD is rarely diagnosed, despite its likely frequency, given the high prevalence of other functional neurological conditions (Carson and Lehn, 2016).

In addition to under-diagnosis due to diagnostic difficulty, some clinicians will be using other terms for the same condition in different settings (Blackburn *et al.*, 2014; Bailey *et al.*, 2017). Also, some clinicians may be avoiding naming the condition at all, or fall back on classifying the patient as either SCD or MCI (which are descriptive rather than aetiological categories). Some practitioners use the term “worried well”, presumably as a means of identifying a group of individuals whose symptoms aren’t due to underlying neurodegeneration. This is unsatisfactory to patients, who are generally not reassured when told their symptoms have no underlying pathological basis, but aren’t offered an alternative explanation. It also hinders efforts to *positively* identify a distinct group. The situation is improving with diagnostic systems e.g., DSM-5 (American Psychiatric Association, 2013), recently switching to emphasise positive criteria for diagnosis rather than identifying Functional Neurological Disorder (FND) solely by the absence of neurological, psychiatric or other general medical explanatory causes.

Here, we propose an operational definition for FCD (Text box 2), which we hope will enable clearer communication in the clinical setting, and standardisation for research purposes. This definition is in line with the DSM-5 definition of FND[[1]](#footnote-1). The key to diagnosing FCD is identifying positive evidence of internal inconsistency (see Text Box 1). However, we have also included a list of mimics (Text Box 3) – situations with a flavour of internal inconsistency but that should prompt consideration of alternative diagnoses. We recognise this is a changing field; these criteria represent a work in progress.

It is important to note that DSM-5 FND includes only sensory and motor (not cognitive) phenotypes. We envisage FCD as the equivalent cognitive phenotype (and we would recommend DSM to consider this in their next revision). Placing FCD within the broader FND umbrella recognises the phenotypic overlap across functional disorders, which includes similarities in neurocognitive profiles (Teodoro *et al.*, 2018). Thus the “cognitive fog” often described by patients with functional movement disorder or dissociative seizures can be conceptualised as part of the same broad condition. Although our mechanistic understanding of FND is incomplete, it is notable that neurobiological models of FND make no distinction between the mechanism of different symptom types. Motor, sensory, cognitive and interoceptive symptoms can all conceivably arise from the same basic malfunction proposed to occur in FND, which is entirely consistent with the common co-occurrence of multiple functional symptoms in the same individual (Edwards *et al.*, 2012; Van den Bergh *et al.*, 2017).

We also feel DSM’s “associated features supporting diagnosis” for FND generally apply to FCD in particular, namely: a history of multiple somatic symptoms; stress or trauma at onset; and dissociative symptoms (though none of these features are necessary for diagnosis, and absence should not lead to the diagnosis being withheld). Finally, we also feel it is helpful to include a specifier for presence or absence of any comorbidity that is linked to the cognitive symptoms. A non-exhaustive list includes health anxiety, mild Traumatic Brain Injury (mTBI), depression, fibromyalgia or Alzheimer’s pathology. Such comorbidities can influence the way people with FCD present, and the types of interventions they might respond to. As an illustration, systematic reviews have suggested that whilst mTBI is sometimes accompanied by temporary effects on attention, processing speed and memory, there is evidence of good recovery beyond the initial weeks and months (Carroll *et al.*, 2014; Cassidy *et al.*, 2014). This makes it possible that many of the self-reported symptoms outside this time frame may have a functional disorder aetiology. The situation is often clarified by the clinician’s re-assessment of the reported severity of the head injury and surrounding circumstances; a Cognitive Behavioural Therapy framework is often helpful to understand how expectations may drive behavioural responses to the injury (van Gils *et al.*, 2020). An operational definition of FCD provides the opportunity for the TBI field to quantify the prevalence of a functional component to cognitive symptomatology.

In cognitive clinics, patients with FCD are typically encountered following symptom duration of at least six months. However, there is no clear need to wait for this duration before making an FCD diagnosis if positive indicators are present. Recent-onset cases may be harder to diagnose than persistent cases, and this would alter the differential diagnosis. It would also be important to avoid over-diagnosis of short-lived forgetting that is within the normal human experience. However, substantial clinical benefit could be gained from making and communicating an FCD diagnosis early, rather than subjecting the patient to prolonged diagnostic limbo.

Substantial heterogeneity in severity can be seen within FCD, as illustrated in Figures 1 and 2. Depending on the level of associated impairment, FCD cases may often additionally meet the definition of one of SCD, MCI or dementia. However, these purely descriptive classifications should be used with great caution (regardless of suspected underlying aetiology). This is because they have come to be associated with progressive neuropathology; if, however, the cognitive presentation is being driven by a functional disorder, then greater impairment does not have the same implications regarding irreversible progression. The adoption of a definition for FCD opens the door to *testing* whether an “FCD subtype of MCI” would contribute to sample stratification in biomarker or intervention studies, and also aid communication of likely outcome and potential treatment.

A diagnosis of FCD would be excluded if another condition better accounted for the symptoms, such as cognitive symptoms that occur as part of a depressive episode, sometimes termed “depressive pseudo-dementia”. The temporal relationship, severity of depression, and the pattern of impairments can inform this distinction. Note that cognitive symptoms may not resolve on depressive episode resolution (Rock *et al.*, 2014). Of patients referred to a tertiary neuropsychiatry clinic, half of those meeting FCD criteria had co-morbid depression (and therefore half did not) (Bhome *et al.*, 2019a). In addition, subthreshold generalised anxiety disorder, dysthymia, and obsessive-compulsive personality traits are commonly noted and appear to be aetiologically relevant in many cases. We hope that our definition can enable research to better quantify rates and relevance of comorbidities and other external factors, in FCD and in comparison to those in other groups (such as healthy controls, and those with early neurodegeneration). Patients with functional disorders often find themselves falling between different specialties, and individual clinicians often feel they are not best placed to offer management. We consider that clinicians working in all specialties that diagnose cognitive disorders should have the skills to recognise FCD, and can play an important part in its management (e.g., (Carson *et al.*, 2016)). Heterogeneity within FCD means that some patients may be relatively straightforward to identify, and management should begin with an explanation of the symptoms and giving a positive diagnosis; others may require referral tailored to unravelling a diagnostic challenge; and others may be best managed within a mental health model.

**Better appreciation of FCD would enhance outcomes across the cognitive field**

Research is ongoing to identify positive features in clinical assessment that point to a functional cognitive diagnosis (for a review see (McWhirter *et al.*, 2019)). When found, it is usually very helpful to *transparently* discuss these internal inconsistencies and their implications with the patient (Stone and Edwards, 2012). These features can also be used to form testable hypotheses. For example, we could predict that amongst people with cognitive symptoms, those displaying internal inconsistency would be:

* More likely to respond to certain treatments (e.g., treatments to modify metacognition)
* More likely to remain stable or improve their cognitive scores, and less likely to eventually develop dementia
* Less likely to have biomarkers of Alzheimer’s or global neurodegeneration.

It may actually be easier to identify those who meet criteria for FCD, than those who have underlying Alzheimer’s pathology, due to the limited access and imperfect precision of current Alzheimer’s biomarkers. In other words, neurodegeneration clinical trial candidates should not just meet SCD or MCI criteria, but also lack the positive features of functional cognitive conditions, in order to enhance power to detect effective Alzheimer’s disease modifiers. On the other hand, to understand processes and efficacy at the population level, particularly in the older age bracket, it may be more appropriate to use dimensional scales (rather than exclusions) to quantify the separate effects of comorbidities, drug toxicity, psychological and lifestyle factors, and FCD.

Improving our identification of key characteristics of FCD, and the many often-interwoven aetiologies behind MCI, should simultaneously improve identification of those who *are* in the prodromal stage of neurodegeneration. Doing so requires thorough assessment of other likely aetiological contributors, as well as examining patterns of “reversion” as well as “conversion”. This could provide greater signal relative to noise, both in understanding biological processes of neurodegeneration, and in testing interventions. Establishing FCD as an essential axis in cognitive assessment will help us to better understand, and ultimately modify, the causes of cognitive impairment, and to determine who will and who will not develop dementia.

# Data availability statement

Not applicable.

# Funding information

HB is funded by a National Institute for Health Research (NIHR) Clinical Lectureship. RB is supported by a NIHR Academic Clinical Fellowship. DB is funded by ARUK & Rosetrees. DB, MReuber and AV acknowledge the support of the National Institute for Health Research Sheffield Biomedical Research Centre (Translational Neuroscience). ME is funded by NIHR and MRC. SF is funded by the Wellcome Trust & the Royal Society. JH is funded by a Wellcome Clinical Research Career Development Fellowship. RH, NF, JSchott and MRossor acknowledge the support of the National Institute for Health Research University College London Hospitals Biomedical Research Centre. LM receives philanthropic funding from Baillie Gifford. TN is funded by an NIHR Clinician Scientist Award. CP is funded by the Innovative Medicines Initiative, BRACE, and the David Telling Charitable Trust. JStone is supported by a National Research Scotland Career Researcher Fellowship. This publication presents independent research; the views expressed are those of the authors and not necessarily those of the specified funding bodies.

# Competing Interests

AC runs a not for profit website www.headinjurysymptoms.org, is a paid associate editor of JNNP, is unpaid treasurer of the functional neurological disorders society, and gives independent testimony in court on a range of topics including functional cognitive disorders. JI received an honorarium for an advisory board for Biogen (2018) on treatments for Alzheimer's disease, has received conference expenses from Roche and has been Principal Investigator on clinical trials in Alzheimer's disease funded by Roche, Merck and Lupin Pharmaceuticals. LM provides independent medical testimony in court cases regarding patients with functional disorders. MReuber has received speaker’s fees from UCB Pharma, Eisai and LivaNova, and benefitted from an educational grant from UCB Pharma; he receives payments from Elsevier as Editor-in-Chief of Seizure, and authorship fees for book publications from Oxford University Press. JStone reports independent expert testimony work for personal injury and medical negligence claims, royalties from UpToDate for articles on functional neurological disorder, is unpaid secretary of the Functional Neurological Disorder Society and runs a free non-profit self-help website for FND, [www.neurosymptoms.org](http://www.neurosymptoms.org) . AV has received consulting fees and travel support from Biogen and Merck.

# Figure Legends

**Figure 1: Where FCD fits in relation to other key terminology used in the cognitive clinic. “**Objective cognitive impairment” denotes low scores on standardized testing. “Subjective cognitive concern” denotes an individual’s perception of their cognitive difficulties (note some patients with MCI and dementia lack insight). Patients with FCD account for a proportion of those with MCI, and a proportion of those with SCD; rarely, those with FCD can meet criteria for dementia (i.e., severe enough to interfere with daily function and independence). Crosses represent biomarkers for neurodegenerative conditions. Biomarkers are clustered most densely among people with dementia; a small number of true positive biomarkers also exist in the healthy population with neither subjective concerns nor objective impairment (indicating neurodegenerative tendency that has not yet manifest), and some will be false positives because a biomarker with 100% specificity seems unlikely (see (McWhirter *et al.*, 2019) for further discussion).

**Figure 2: Trajectories in FCD (after (McWhirter *et al.*, 2019)).** This illustrates the wide spectrum of potential trajectories within FCD, highlighting that some patients have considerable persisting symptoms and impairment even after serial testing, whereas others return to baseline functioning. The causes of these divergent trajectories may be explicable via comorbidities or external factors, but often no such factors are identified. Disentangling this heterogeneity is an important area for future research. The x axis represents each lifetime; those who remain above the x-axis to the end of their lifetime have died from other causes.

References made within text boxes:

(Alexander *et al.*, 2019)

(Bharambe and Larner, 2018b)

(Bhome *et al.*, 2019b).

(Mirman and Britt, 2014)

(Eichenbaum *et al.*, 2007)

(Crutch *et al.*, 2012))

(Koedam *et al.*, 2010)

# References

Abner EL, Kryscio RJ, Schmitt FA, Fardo DW, Moga DC, Ighodaro ET*, et al.* Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. Annals of neurology 2017; 81(4): 549-59.

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC*, et al.* The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7(3): 270-9.

Alexander M, Blackburn D, Reuber M. Patients' accounts of memory lapses in interactions between neurologists and patients with functional memory disorders. Sociol Health Illn 2019; 41(2): 249-65.

American Psychiatric Association. Somatic Symptom and Related Disorders. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th ed. Washington, DC; 2013.

Bailey C, Bell SM, Blackburn DM. How the UK describes functional memory symptoms. Psychogeriatrics 2017; 17(5): 336-7.

Bharambe V, Larner AJ. Functional cognitive disorders: demographic and clinical features contribute to a positive diagnosis. Neurodegener Dis Manag 2018a; 8(6): 377-83.

Bharambe V, Larner AJ. Functional cognitive disorders: memory clinic study. Prog Neurol Psychiatry 2018b; 22(3): 19-22.

Bhome R, Huntley JD, Price G, Howard RJ. Clinical presentation and neuropsychological profiles of Functional Cognitive Disorder patients with and without co-morbid depression. Cogn Neuropsychiatry 2019a; 24(2): 152-64.

Bhome R, McWilliams A, Huntley JD, Fleming SM, Howard RJ. Metacognition in functional cognitive disorder- a potential mechanism and treatment target. Cogn Neuropsychiatry 2019b; 24(5): 311-21.

Blackburn DJ, Wakefield S, Shanks MF, Harkness K, Reuber M, Venneri A. Memory difficulties are not always a sign of incipient dementia: a review of the possible causes of loss of memory efficiency. Br Med Bull 2014; 112(1): 71-81.

Carroll LJ, Cassidy JD, Cancelliere C, Cote P, Hincapie CA, Kristman VL*, et al.* Systematic review of the prognosis after mild traumatic brain injury in adults: cognitive, psychiatric, and mortality outcomes: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Arch Phys Med Rehabil 2014; 95(3 Suppl): S152-73.

Carson A, Hallett M, Stone J. Assessment of patients with functional neurologic disorders. Handb Clin Neurol 2016; 139: 169-88.

Carson A, Lehn A. Epidemiology. Handb Clin Neurol 2016; 139: 47-60.

Cassidy JD, Cancelliere C, Carroll LJ, Cote P, Hincapie CA, Holm LW*, et al.* Systematic review of self-reported prognosis in adults after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Arch Phys Med Rehabil 2014; 95(3 Suppl): S132-51.

Creese B, Brooker H, Ismail Z, Wesnes KA, Hampshire A, Khan Z*, et al.* Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2019; 27(8): 823-34.

Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol 2012; 11(2): 170-8.

Edwards MJ, Adams RA, Brown H, Parees I, Friston KJ. A Bayesian account of 'hysteria'. Brain 2012; 135(Pt 11): 3495-512.

Eichenbaum H, Yonelinas AP, Ranganath C. The Medial Temporal Lobe and Recognition Memory. Annual Review of Neuroscience 2007; 30(1): 123-52.

Elsey C, Drew P, Jones D, Blackburn D, Wakefield S, Harkness K*, et al.* Towards diagnostic conversational profiles of patients presenting with dementia or functional memory disorders to memory clinics. Patient education and counseling 2015; 98(9): 1071-7.

Ferrer I. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog Neurobiol 2012; 97(1): 38-51.

Ganguli M, Jia Y, Hughes TF, Snitz BE, Chang C-CH, Berman SB*, et al.* Mild Cognitive Impairment that Does Not Progress to Dementia: A Population-Based Study. J Am Geriatr Soc 2019; 67(2): 232-8.

Howard R. Subjective cognitive decline: what is it good for? The Lancet Neurology 2020.

Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW*, et al.* Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9(1): 119-28.

Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL*, et al.* The characterisation of subjective cognitive decline. The Lancet Neurology 2020.

Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA. Early-versus late-onset Alzheimer's disease: more than age alone. Journal of Alzheimer's disease : JAD 2010; 19(4): 1401-8.

Latimer CS, Keene CD, Flanagan ME, Hemmy LS, Lim KO, White LR*, et al.* Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies. J Neuropathol Exp Neurol 2017; 76(6): 458-66.

Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D*, et al.* Dementia prevention, intervention, and care. The Lancet 2017; 390(10113): 2673-734.

McWhirter L, Ritchie C, Stone J, Carson A. Functional cognitive disorders: a systematic review. Lancet Psychiatry 2019; In Press.

Mirman D, Britt AE. What we talk about when we talk about access deficits. Philos Trans R Soc Lond B Biol Sci 2014; 369(1634): 20120388.

Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ*, et al.* Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. Journal of neuropathology and experimental neurology 2012; 71(5): 362-81.

Pennington C, Ball H, Swirski M. Functional Cognitive Disorder: Diagnostic Challenges and Future Directions. Diagnostics (Basel) 2019; 9(4).

Pennington C, Hayre A, Newson M, Coulthard E. Functional Cognitive Disorder: A Common Cause of Subjective Cognitive Symptoms. Journal of Alzheimers Disease 2015a; 48: S19-S24.

Pennington C, Newson M, Hayre A, Coulthard E. Functional cognitive disorder: what is it and what to do about it? Practical neurology 2015b; 15(6): 436-44.

Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Intern Med 2014; 275(3): 214-28.

Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychological Medicine 2014; 44(10): 2029-40.

Schmidtke K, Pohlmann S, Metternich B. The syndrome of functional memory disorder: definition, etiology, and natural course. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2008; 16(12): 981-8.

Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Annals of neurology 2009; 66(2): 200-8.

Stephan BC, Hunter S, Harris D, Llewellyn DJ, Siervo M, Matthews FE*, et al.* The neuropathological profile of mild cognitive impairment (MCI): a systematic review. Mol Psychiatry 2012; 17(11): 1056-76.

Stone J, Edwards M. Trick or treat? Showing patients with functional (psychogenic) motor symptoms their physical signs. Neurology 2012; 79(3): 282-4.

Stone J, Pal S, Blackburn D, Reuber M, Thekkumpurath P, Carson A. Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimers Disease 2015; 48: S5-S17.

Teodoro T, Edwards MJ, Isaacs JD. A unifying theory for cognitive abnormalities in functional neurological disorders, fibromyalgia and chronic fatigue syndrome: systematic review. Journal of Neurology Neurosurgery and Psychiatry 2018; 89(12): 1308-19.

Van den Bergh O, Witthöft M, Petersen S, Brown RJ. Symptoms and the body: Taking the inferential leap. Neuroscience & Biobehavioral Reviews 2017; 74: 185-203.

van Gils A, Stone J, Welch K, Davidson LR, Kerslake D, Caesar D*, et al.* Management of mild traumatic brain injury. Practical Neurology 2020: practneurol-2018-002087.

van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P*, et al.* Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol 2019; 18(11): 1034-44.

Wakefield SJ, Blackburn DJ, Harkness K, Khan A, Reuber M, Venneri A. Distinctive neuropsychological profiles differentiate patients with functional memory disorder from patients with amnestic-mild cognitive impairment. Acta Neuropsychiatr 2018; 30(2): 90-6.

1. We also considered whether FCD could fit within DSM-5’s Somatic Symptom Disorder (SSD). However, SSD does not actually capture elements of FCD that we feel are integral (i.e., internal inconsistency), so does nothing to aetiologically disentangle FCD from prodromal Alzheimer’s disease (which can involve similar levels of anxiety). SSD also does not account for those with FCD without a significant anxiety component. [↑](#footnote-ref-1)